Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis
| dc.contributor.author | Efe, Cumali | |
| dc.contributor.author | Lammert, Craig | |
| dc.contributor.author | Tascilar, Koray | |
| dc.contributor.author | Dhanasekaran, Renumathy | |
| dc.contributor.author | Ebik, Berat | |
| dc.contributor.author | Higuera-de la Tijera, Fatima | |
| dc.contributor.author | Caliskan, Ali R. | |
| dc.date.accessioned | 2024-02-23T14:24:32Z | |
| dc.date.available | 2024-02-23T14:24:32Z | |
| dc.date.issued | 2022 | |
| dc.department | NEÜ | en_US |
| dc.description.abstract | Background We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH. | en_US |
| dc.description.sponsorship | Italian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic) | en_US |
| dc.description.sponsorship | A. Gerussi, L. Cristoferi, and P. Invernizzi acknowledge that this research was partially supported by the Italian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic). | en_US |
| dc.identifier.doi | 10.1111/liv.15121 | |
| dc.identifier.endpage | 614 | en_US |
| dc.identifier.issn | 1478-3223 | |
| dc.identifier.issn | 1478-3231 | |
| dc.identifier.issue | 3 | en_US |
| dc.identifier.pmid | 34846800 | en_US |
| dc.identifier.scopus | 2-s2.0-85121047570 | en_US |
| dc.identifier.scopusquality | Q1 | en_US |
| dc.identifier.startpage | 607 | en_US |
| dc.identifier.uri | https://doi.org/10.1111/liv.15121 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12452/13996 | |
| dc.identifier.volume | 42 | en_US |
| dc.identifier.wos | WOS:000729531700001 | en_US |
| dc.identifier.wosquality | Q1 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.indekslendigikaynak | PubMed | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Wiley | en_US |
| dc.relation.ispartof | Liver International | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Autoimmunity | en_US |
| dc.subject | Azathioprine | en_US |
| dc.subject | Budesonide | en_US |
| dc.subject | Liver Transplantation | en_US |
| dc.subject | Mercaptopurine | en_US |
| dc.subject | Sars-Cov-2 | en_US |
| dc.title | Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis | en_US |
| dc.type | Article | en_US |












